Advances in Expansion Technologies for the Clinical-Scale Production of MSCs

In by

Spotlight Article


Steve Oh

Separation and Expansion Technologies


Steve Oh is the Director of Stem Cell Bioprocessing and Institute, Professor/Scientist of the Bioprocessing Technology Institute (BTI) and an expert in integrated stem cell bioprocessing for the manufacture of human pluripotent/embryonic and adult mesenchymal stem cells (MSCs) for cell therapies. Key recent achievements include high density production of pluripotent stem cells, cardiomyocytes, neuroprogenitors and red blood cells in suspension bioreactors. In the MSC area, methods of producing high-quality MSCs, and primed towards cartilage and bone repair have been achieved. Recently a new assay for stem cell senescence useful for the quality control of stem cells for bioprocesses has been developed by his team. He has over 100 publications and 25 patents in stem cells production. He was the International Society of Cellular Therapies (ISCT) Co-Vice President (Asia) from 2015 to 2017, and led the planning of the Sessions for Commercialisation of Cell Therapies for the Silver Jubilee (25 years) ISCT meeting at Suntec City, Singapore in 2016. He is also the current Vice President of the Singapore Stem Cell Society and holds an Adjunct Professorship at the Nanyang Technological University. Steve has founded two stem cell companies, Brilliant Research and Veristem, and is a veteran of 26 years in the biotech industry. Brilliant Research is a company specializing in providing Personalised Stem Cell Banking and Stem Cell Bioprocess solutions to build the 3rd Pillar of Medicine, Cell & Gene Therapies.

DOI: 10.18609/cgti.2018.006
Citation: Cell Gene Therapy Insights 2018; 4(1), 45-49.
Open access

This content is restricted to registered users. Click here to Register or Login here.